Advancing state-of-the-art precision medicine.
We envision a world where people are enabled to make better choices for a better life.
Existing precision medicines target just 10% of cancers – those with DNA mutations in oncogenic drivers for a small number of genes. OncXerna is transforming precision medicine beyond single genetic mutations by discovering the dominant biology of a person’s cancer at the RNA level to advance more meaningful treatments for more cancer patients.
Arctic Vision is a China-based clinical stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company’s vision is to address ophthalmology’s unmet needs through innovative therapies in China, Asia and globally. Arctic Vision is established by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products.
Acquiring, developing and commercializing transformative medicines in neuroscience.
We aim to become an elite innovative neuroscience company addressing China specific unmet medical needs with top notch development and commercial capabilities.
We aspire to bridge the gap of innovative neuroscience treatments between China and global leaders by bringing their breakthrough therapies to make patient lives better in China and Asia.
We are led by a world-class neuroscience veteran team with proven track records and repeated successes in developing and commercializing CNS drugs in China and Asia.
We are backed by top-tier biotech venture capitals with broad network worldwide, in-depth knowledge and unprecedent track records in new venture incubation in China.
VISEN Pharmaceuticals is committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market, and hoping to provide more Chinese patients quick access to the world's most advanced and reliable treatment solutions.